These two stocks are in the limelight since the start of this year: Sunrun Inc. (RUN) and Acorda Therapeutics Inc. (ACOR)

On Nov 26, STEELE JEANNA, General Counsel sold 896 shares of Sunrun Inc. (NASDAQ: RUN), with the average selling price of the stock being $13.74 per share. The total amount realized from this sold $12,311. A document was filed with the Securities and Exchange Commission to notify the public about the sold of the shares.

In addition to that, Chief Accounting Officer – Philpot Michelle sold an extra 1,098 shares of this stock in a transaction that took place a day before, on Nov 22, with a share sold at an average of $13.47 and a total of $14,790 was realized from this transaction. After the transaction, the Chief Accounting Officer – Philpot Michelle was left with 50,474 shares of the company’s stock, which is currently worth around $679884.78.

The recent price movement of RUN means that it is now down by -35.20% from its 52-week high and 57.55% up against its 52-week low prices. Over the past one week, the price volatility of RUN stands at 2.20% while the volatility over the past one month is 4.26%. The beta score for this stock is 0.67. A beta score below 1 means that the stock has a low volatility while above 1 signifies that a stock is highly volatile at that particular moment, a data that traders use to keep tabs on their investments.

The company on 11/12/2019 published its latest quarterly earnings, with the report showing that the company recorded -0.05 earnings per share (EPS) during that period. This report was below the expectations of analysts of 0.27 by -0.32. The revenue by the firm was 228.42M for the quarter.

The shares of Sunrun Inc. (RUN) dropped by -0.79%, leading to a loss of -$0.11 per share, and saw RUN end the trading session at $13.88 on Friday 11/29/19. RUN started the trading session at $13.81, before reaching a daily high of $14.09. It wasn’t able to sustain that growth though and soon jumped to hit a daily low of $13.80.

The trading volume on Friday stood at 715081, which was below the stock’s 3-month average volume of 1.71 million shares, out of a total 111.81M shares. As the price of the stock dipped, the market valuation of the company dropped to 1.65 billion.

The shares of Acorda Therapeutics Inc. (NASDAQ: ACOR) went down by -8.57% by the end of the recent trading session. This movement saw its price plunge to close at $1.60, which was lower than the previous closing price of $1.75. Over the past one week, the price of ACOR has slipped by -7.51%, while it has recorded a loss of -12.57% over the past one month. Its three-month performance saw ACOR lose -50.46% while its six-month performance saw it drop by -82.96%. The situation is different though over the past one year, as the stock price went down by -92.31%, while its year-to-date (YTD) price performance slipped by -89.73%. The stock price has gone up by +7.38% compared to its 90-day low, while it is down -64.13% compared to its 90-day high price.

Let’s take a look at its short, medium and long-term indicators. Composite Indicators shows that Trendspotter rated the stock as a Sell. In the short-term, the stock has a 20-day average volume of 1,757,915 shares, with the short-term indicators averagely rating the stock as a 100% Sell. A look at its medium-term indicators reveals that it has a 50-Day average volume of 1,621,732 shares and the indicators have an average rating of 100% Sell. The last indicators, the long-term see ACOR stock with a 100-Day average volume of 1,680,073 shares, giving it an average rating of 100% Sell. A look at the general picture of all short, medium and long-term indicators leaves ACOR with an average rating of 100% Sell.

Several brokerage firms sent out their reports ACOR stock not long ago. In its report sent out on August 14, 2019, H.C. Wainwright lowered its ratings on ACOR from a Buy to a Neutral. In an earlier report on May 23, 2019, Wedbush Initiated the stock to a Neutral. Goldman meanwhile in its report on December 11, 2018 Downgrade its rating of the stock from a “Sell” to “Sell”.

In a recent SEC filing, the company revealed that 188 institutions currently hold the ACOR stock. In the last quarter, a 55,605,601 ACOR shares were in the possession of institutions.